Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563797 · ClinicalTrials.gov registry record · Phase 3
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT00563797 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 21 participants.
The verdict
NCT00563797, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce depressive symptoms and decrease alcohol consumption compared to placebo in patients with depression and alcohol dependence who are on a stable dose of a selective serotonin reuptake inhibitor (SSRI).
Interventions
- DRUG Placebo
- DRUG Mecamylamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563797
The ClinicalTrials.gov registry entry for NCT00563797 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00563797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00563797 about?
NCT00563797 is a clinical study titled "Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence". The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce depressive symptoms and dec...
What is the current status of trial NCT00563797?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2007-08. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00563797?
The interventions under investigation include: Placebo (DRUG), Mecamylamine (DRUG).
Who is sponsoring clinical trial NCT00563797?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.